Palo Alto Investors L.P. 13F annual report

Palo Alto Investors L.P. is an investment fund managing more than $863 billion ran by Angela Nguyen-dinh. There are currently 39 companies in Mrs. Nguyen-dinh’s portfolio. The largest investments include Insmed Inc and Biomarin Pharmaceutical, together worth $236 billion.

$863 billion Assets Under Management (AUM)

As of 7th August 2024, Palo Alto Investors L.P.’s top holding is 2,138,963 shares of Insmed Inc currently worth over $143 billion and making up 16.6% of the portfolio value. Relative to the number of outstanding shares of Insmed Inc, Palo Alto Investors L.P. owns more than approximately 0.1% of the company. In addition, the fund holds 1,130,167 shares of Biomarin Pharmaceutical worth $93 billion, whose value grew 5.8% in the past six months. The third-largest holding is Amicus Therapeutics Inc worth $89.6 billion and the next is United Therapeutics Corp worth $85 billion, with 266,914 shares owned.

Currently, Palo Alto Investors L.P.'s portfolio is worth at least $863 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Palo Alto Investors L.P.

The Palo Alto Investors L.P. office and employees reside in Palo Alto, California. According to the last 13-F report filed with the SEC, Angela Nguyen-dinh serves as the Chief Compliance Officer at Palo Alto Investors L.P..

Recent trades

In the most recent 13F filing, Palo Alto Investors L.P. revealed that it had opened a new position in Alnylam Pharmaceuticals Inc and bought 183,123 shares worth $44.5 billion. This means they effectively own approximately 0.1% of the company. Alnylam Pharmaceuticals Inc makes up 5.6% of the fund's Health Care sector allocation and has grown its share price by 47.6% in the past year.

The investment fund also strengthened its position in Staar Surgical Co by buying 2,029 additional shares. This makes their stake in Staar Surgical Co total 1,381,619 shares worth $65.8 billion. Staar Surgical Co dropped 13.4% in the past year.

On the other hand, there are companies that Palo Alto Investors L.P. is getting rid of from its portfolio. Palo Alto Investors L.P. closed its position in Alnylam Pharmaceuticals Inc on 14th August 2024. It sold the previously owned 182,766 shares for $27.3 billion. Angela Nguyen-dinh also disclosed a decreased stake in Insmed Inc by 0.5%. This leaves the value of the investment at $143 billion and 2,138,963 shares.

One of the average hedge funds

The two most similar investment funds to Palo Alto Investors L.P. are Atika Capital Management and Quinn Opportunity Partners. They manage $863 billion and $862 billion respectively.


Angela Nguyen-dinh investment strategy

Palo Alto Investors L.P.’s portfolio is diversified across 3 sectors. Currently, their heaviest sector is Health Care — making up 92.5% of the total portfolio value. The fund focuses on investments in the United States as 76.9% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are large-cap stocks. Stocks with a size of more than $10 billion in market cap make up 18% of the total holdings value. On the other hand, small-cap stocks make up only 5.1% of the portfolio. The average market cap of the portfolio companies is close to $7.37 billion.

The complete list of Palo Alto Investors L.P. trades based on 13F SEC filings

These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security Shares Owned Value Allocation
Insmed Inc
51.64%
2,138,963
$143,310,521,000 16.61%
Biomarin Pharmaceutical Inc.
0.39%
1,130,167
$93,046,649,000 10.78%
Amicus Therapeutics Inc
3.36%
9,029,843
$89,576,043,000 10.38%
United Therapeutics Corp
0.32%
266,914
$85,025,455,000 9.85%
Biogen Inc
0.31%
289,050
$67,007,571,000 7.76%
Staar Surgical Co.
0.15%
1,381,619
$65,778,881,000 7.62%
Alnylam Pharmaceuticals Inc
Opened
183,123
$44,498,889,000 5.16%
Acadia Pharmaceuticals Inc
0.16%
2,418,841
$39,306,166,000 4.55%
Prothena Corp Plc
0.18%
1,666,378
$34,394,042,000 3.99%
Sarepta Therapeutics Inc
0.21%
201,683
$31,865,914,000 3.69%
Alnylam Pharmaceuticals Inc
Closed
182,766
$27,314,379,000
AnaptysBio Inc
0.47%
803,641
$20,139,243,000 2.33%
Iovance Biotherapeutics Inc
0.17%
2,116,403
$16,973,552,000 1.97%
Revance Therapeutics Inc
0.17%
5,257,086
$13,510,711,000 1.57%
Alkermes plc
No change
495,592
$11,943,767,000 1.38%
Sage Therapeutics Inc
0.50%
1,010,833
$10,977,646,000 1.27%
eHealth Inc
13.46%
2,350,190
$10,646,361,000 1.23%
NovoCure Ltd
No change
561,908
$9,625,484,000 1.12%
Align Technology, Inc.
23.08%
37,772
$9,119,294,000 1.06%
Syndax Pharmaceuticals Inc
No change
405,193
$8,318,612,000 0.96%
Acelyrin Inc
No change
1,715,180
$7,563,944,000 0.88%
Nevro Corp
No change
750,371
$6,318,124,000 0.73%
Cytokinetics Inc
No change
111,717
$6,052,827,000 0.70%
Gossamer Bio, Inc.
1.79%
6,277,093
$5,655,033,000 0.66%
Elevation Oncology Inc
33.67%
1,800,106
$4,860,286,000 0.56%
Bluebird bio Inc
1.60%
4,633,351
$4,560,144,000 0.53%
Karyopharm Therapeutics Inc
No change
5,102,193
$4,426,663,000 0.51%
Verve Therapeutics Inc
No change
575,817
$2,809,987,000 0.33%
Nuvation Bio Inc
No change
772,652
$2,256,144,000 0.26%
Mirum Pharmaceuticals Inc
No change
64,700
$2,212,093,000 0.26%
Relmada Therapeutics Inc
No change
732,400
$2,197,200,000 0.25%
Taysha Gene Therapies, Inc.
No change
811,268
$1,817,240,000 0.21%
Stoke Therapeutics, Inc.
No change
125,861
$1,700,382,000 0.20%
Humana Inc.
No change
3,985
$1,488,995,000 0.17%
Travere Therapeutics Inc
No change
110,719
$910,110,000 0.11%
Vyne Therapeutics Inc Pipe
No change
445,434
$877,505,000 0.10%
Aldeyra Therapeutics Inc
No change
225,465
$746,289,000 0.09%
Aclaris Therapeutics Inc
No change
569,832
$626,815,000 0.07%
Generation Bio Co.
Opened
150,475
$424,340,000 0.05%
UroGen Pharma Ltd
No change
24,500
$411,110,000 0.05%
No transactions found
Showing first 500 out of 40 holdings